Group 1: Financial Performance - The company experienced a loss in the first half of 2025 due to multiple factors including macroeconomic slowdown, ongoing procurement policies, and intensified industry competition [2] - Total expenses for sales, management, and R&D decreased by 16% year-on-year, enhancing operational efficiency [5] - Cash flow increased by 97.07% year-on-year, indicating improved financial health [6] Group 2: International Market Strategy - The international business grew by 24% year-on-year, with significant growth in key markets such as India, Asia-Pacific, and Turkey [3] - The company has over 20 years of experience in overseas operations, focusing on local management to enhance brand value [3] Group 3: Strategic Adjustments - A new management team with industry backgrounds is conducting a strategic review to enhance the company's operational effectiveness [4] - The company aims to focus on three core areas in the second half of 2025: expanding international markets, accelerating domestic equipment installation, and optimizing the supply chain [2] Group 4: R&D and Technological Advancements - The company launched a fully automated urine analyzer, achieving high precision in identifying 50 types of cells [6] - Progress in AI integration within medical technology is being pursued, with advancements in intelligent recognition systems for medical imaging [7] Group 5: Cost Management - Financial expenses saw a significant reduction due to improved fund management and currency risk control, with interest income increasing by approximately 1.391 million [6] - The company implemented precise resource allocation in marketing, leading to enhanced cost efficiency [5]